Treatment with Specified Products
Dear Royal Free London NHS Foundation Trust,
Could you please provide answers to the following questions, with regards to treatments with the specified products:
1) in the past 6 months, how many patients were treated with a combination of both Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:
A) Metastatic Melanoma
B) Colorectal Cancer
C) Any other indications
2) In the past 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:
A) Metastatic Melanoma
B) Adjuvant Melanoma
C) BRAF mutated Lung Cancer
Thank you for answering these questions
Yours faithfully,
BEN HOLDSWORTH
This is the mail system at host smtp2.e.amses.net.
I'm sorry to have to inform you that your message could not
be delivered to one or more recipients. It's attached below.
For further assistance, please send mail to postmaster.
If you do so, please include this problem report. You can
delete your own text from the attached returned message.
The mail system
<[Royal Free London NHS Foundation Trust request email]>: host nhs.mail.protection.outlook.com[52.101.99.0] said: 550
5.4.1 Recipient address rejected: Access denied.
[CW2PEPF000056BF.GBRP265.PROD.OUTLOOK.COM 2024-01-23T15:30:32.693Z
08DC1C06D32A8FBE] (in reply to RCPT TO command)
We work to defend the right to FOI for everyone
Help us protect your right to hold public authorities to account. Donate and support our work.
Donate Now